Linagliptin is a dipeptidyl peptidase-4 inhibitor that reduces blood sugar by increasing insulin and decreasing glucagon production by the pancreas, used to treat diabetes mellitus type 2. The gene discussed is INS; the disease is type 2 diabetes mellitus.